FDA Advises US Navy That It May Not Initiate A Clinical Trial of Biopure's Product Hemopure
Tweet Send to a Friend
Biopure Corporation (Nasdaq: BPUR) announced that the FDA has advised the U.S. Naval Medical Research Centerby letter that it may ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
